Nevertheless, different antihypertensive pharmacological treatments were associated with different protection against severe COVID-19, as a large nationwide retrospective cohort study showed that antihypertensive people exposed to ACE inhibitors or ARBs were at less risk of hospitalization with COVID-19 and less risk of intubation or death compared with individuals exposed to CCBs [70], pointing to a crucial role of RAS in COVID-19 pathology (see Section 4). The gene discussed is ACE; the disease is COVID-19.